In the context of deletional CD8+ T cell tolerance mediated by cDC1s, we have shown that targeting cDC1 activation with toll-like receptor (TLR), CD40, or simulator of interferon genes (STING) agonists can be effective in restoring functional anti-leukemia CD8+ T cell responses (Curran et al., 2016; Kline et al., 2018; Zhang et al., 2013). Here, STING1 is linked to leukemia.